Vantage logo

Freenome aims to take on the big beasts

Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.